ICSN3250

Research use only, not for human use.

ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.

ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors; ICSN3250 is not a kinase inhibitor of mTOR, competes with and displaces phosphatidic acid from the FRB domain in mTOR, thus preventing mTOR activation and leading to cytotoxicity; displays no inhibitory capacity towards PI3Kα, β, γ, or δ; inhibits mTORC1 by following an unprecedented mechanism that involved its competition with PA at the FRB domain of mTOR to overcome the TSC negative regulation of mTORC1; ICSN3250 specifically targets cancer cells both in vitro and ex vivo.

——

——

ICSN-3250

PI3K/Akt/mTOR signaling

mTOR

mTOR

——

——

1561902-73-5

596.681

C31H40N4O8

>98% (HPLC)

——

C1CCCCCCN(CCCCC1)CCCN2C=C(C(=C2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-])C4=CC(=C(C(=C4)O)O)[N+](=O)[O-]

5,5'-(1-(3-(azacyclotridecan-1-yl)propyl)-1H-pyrrole-3,4-diyl)bis(3-nitrobenzene-1,2-diol)

(-20℃)

With Ice Pack

≥ 2 years